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ABSTRACT
Background: Chronic consumption of dairy products with an SFA-reduced, MUFA-enriched content was shown
to impact favorably on brachial artery flow-mediated dilatation (FMD). However, their acute effect on postprandial
cardiometabolic risk biomarkers requires investigation.
Objective: The effects of sequential high-fat mixed meals rich in fatty acid (FA)–modified or conventional (control) dairy
products on postprandial FMD (primary outcome) and systemic cardiometabolic biomarkers in adults with moderate
cardiovascular risk (≥50% above the population mean) were compared.
Methods: In a randomized crossover trial, 52 participants [mean ± SEM age: 53 ± 2 y; BMI (kg/m2) 25.9 ± 0.5]
consumed a high-dairy-fat breakfast (0 min; ∼50 g total fat: modified: 25 g SFAs, 20 g MUFAs; control: 32 g SFAs, 12 g
MUFAs) and lunch (330 min; ∼30 g total fat; modified: 15 g SFAs, 12 g MUFAs; control: 19 g SFAs, 7 g MUFAs). Blood
samples were obtained before and until 480 min after breakfast, with FMD assessed at 0, 180, 300, and 420 min. Data
were analyzed by linear mixed models.
Results: Postprandial changes in cardiometabolic biomarkers were comparable between the different dairy meals,
with the exception of a tendency for a 4% higher AUC for the %FMD response following the modified-dairy-fat meals
(P = 0.075). Plasma total lipid FA analysis revealed that incremental AUC responses were 53% lower for total SFAs, 214%
and 258% higher for total cis-MUFAs (predominantly cis-9 18:1), and trans-18:1, respectively, following the modified
relative to the control dairy meals (all P < 0.0001).
Conclusions: In adults at moderate cardiovascular risk, acute consumption of sequential high-fat meals containing FA-
modified dairy products had little impact on postprandial endothelial function or systemic cardiometabolic biomarkers,
but a differential effect on the plasma total lipid FA profile, relative to conventional dairy fat meals. This trial was registered
at clinicaltrials.gov as NCT02089035. J Nutr 2021;151:1755–1768.
Keywords: endothelial function, monounsaturated fatty acids, postprandial lipemia, saturated fatty acids,
sequential test meal protocol
Introduction
The replacement of dietary SFAs with unsaturated fatty
acids (FAs) is advised as a key public health strategy for
cardiovascular disease (CVD) risk reduction (1, 2). Milk and
dairy products are a major source of SFAs in the diet (3).
However, it is known that the food matrix can influence
the nutritional properties, nutrient absorption, and associated
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health effects of an SFA-rich food (e.g., cheese) (4). Indeed,
evidence from prospective studies and meta-analyses indicates
that full-fat dairy products are not linked to increased CVD risk,
except for butter fat (4). As dairy products play a substantial
role in meeting essential nutrient requirements, limiting their
consumption to reduce SFA intake may inadvertently affect
public health (5–7).
Exaggerated postprandial triacylglycerol (TG) is an inde-
pendent CVD risk factor, with high-fat meals known to lead
to a transient increase in TG-rich lipoproteins during the
postprandial phase (8, 9). A meta-analysis of postprandial
lipemic responses to single high-fat meals highlighted that, over
an 8-h period, there was a benefit or a tendency towards a
beneficial effect of replacing SFAs (mainly butter) by either
PUFA- or MUFA-rich oils, respectively (10). Additionally,
the type of dairy product incorporated into fat- and FA-
matched meals has been shown to differently affect the
postprandial TG response, with sour cream inducing a larger
TG incremental AUC (iAUC) over 6 h compared with whipped
cream, butter, and cheese (11). However, little is known about
how manipulating the FA composition of high-dairy-fat load
affects postprandial lipemia, particularly using a sequential
2-meal protocol that contains a combination of commonly
consumed dairy products and, thus, more closely reflects real-
life eating patterns.
Postprandial TG may trigger a cascade of proinflammatory
events that lead to endothelial dysfunction, an early event in the
pathogenesis of atherosclerosis (12, 13). Although single high-
fat meals (36–80 g total fat) are known to impair postprandial
endothelial function, including flow-mediated dilatation (FMD)
(14), evidence regarding the comparative effects of test meals
rich in unsaturated FAs with SFAs or different dairy products
on postprandial FMD or biomarkers of endothelial function is
inconclusive (14, 15).
In a proof-of-concept study, we recently reported that 12-
wk intake of SFA-reduced, MUFA-enriched milk, cheese, and
butter (∼41 g dairy fat/d) that were FA-modified via a dairy-
cow feeding strategy (16), attenuated the rise in fasting LDL-
cholesterol concentrations and had a beneficial effect on FMD,
relative to conventional dairy product consumption (17). As
individuals spend up to 18 h/d in the nonfasting state (9, 18),
there is a clear need to gain an understanding of the postprandial
cardiometabolic responses to FA-modified dairy products (5).
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Therefore, we investigated the acute effect of sequential high-
fat mixed meals containing FA-modified dairy products on the
postprandial %FMD response, systemic cardiometabolic risk
biomarkers, and plasma total lipid FA responses in adults with
moderate CVD risk. We hypothesized that meals rich in FA-
modified milk, cheese, and butter would beneficially impact
on the postprandial %FMD response (primary outcome) and
other cardiometabolic risk biomarkers compared with matched
meals containing dairy foods with an FA profile typical of
conventional retail products (control).
Methods
Participants
The REplacement of SaturatEd fat in dairy on Total cholesterol (RESET)
Study was performed at the Hugh Sinclair Unit of Human Nutrition,
University of Reading (Berkshire, UK). Men and women [aged 25–
70 y; BMI (kg/m2)19–32] at moderate CVD risk were recruited from
the Berkshire area between February 2014 and September 2015. To
assist with participant recruitment, the study upper age limit was
extended from 65 y to 70 y in May 2014. Details of the participant
recruitment strategy, inclusion and exclusion criteria, and dietary
intervention are presented in detail elsewhere (17, 19). In brief, a
modified Framingham CVD risk score identified individuals at moderate
risk of developing CVD (≥50% greater CVD risk compared with the
population mean) (19). Eligible participants were nonsmokers with
mild/moderate hypercholesterolemia (fasting total cholesterol ≥5.2–
8.0 mmol/L); not diagnosed with CVD and diabetes (and fasting glucose
concentration <7 mmol/L); not taking medication for hyperlipidemia,
hypertension, hypercoagulation, or inflammation; not pregnant or
lactating; not consuming excessive amounts of alcohol (<14 and 21
units/wk for women and men, respectively); not regularly engaging
in vigorous-intensity aerobic activities (>3 times × 20 min/wk); and
presenting with normal biochemistry for liver and kidney function
(19). The study was given a favorable ethical opinion for conduct
by the University of Reading’s Research Ethics Committee (project
13/43), registered with clinicaltrials.gov (NCT02089035), and carried
out in accordance with the Declaration of Helsinki of 1975, as
revised in 1983. Participants provided written informed consent before
enrollment.
Study design
This trial was an acute randomized, double-blind, sequential-meal,
crossover dietary study nested within the larger RESET proof-of-
concept chronic intervention study, which examined the impact of
long-term consumption of FA-modified dairy products on novel and
traditional markers of CVD risk (17). The chronic intervention study
consisted of two 12-wk dietary periods where FA-modified or control
dairy products were consumed in a randomized crossover manner,
separated by an 8-wk washout period (17). As outlined in Supplemental
Figure 1, the 2 baseline acute study visits were performed prior to
commencing each 12-wk dietary intervention period. With the addition
of the 8-wk washout period, the duration between the acute study visits
examined in the present trial was 20 wk. None of the results reported
here for our subcohort have been previously published. Minimization
was used to randomly allocate participants to their first treatment
(17, 19). The researchers responsible for conducting and/or analyzing
measurements (OM, DV, KEK and RS) and the participants were blinded
to treatment allocations.
Postprandial 2-meal protocol
A sequential 2-meal protocol was used to examine the effect of dairy FA
manipulation on postprandial endothelial function and cardiometabolic
responses. The details of our high-oleic sunflower oil (HOS) dairy-cow
feeding strategy, as well as the production, FA profile, and consumer
acceptance of the FA-modified milk and dairy products, are published
elsewhere (16, 20).
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TABLE 1 Nutritional composition of the sequential high-fat mixed test breakfast (0 min) and lunch
meals (330 min) that incorporated the fatty acid–modified or conventional (control) dairy products1
Modified Control
Breakfast Lunch Total Breakfast Lunch Total
Energy,2 MJ 4.3 2.6 6.9 4.1 2.5 6.6
Total fat,2 g 50.6 30.6 81.2 49.9 30.3 80.2
SFAs,3 g 24.5 14.8 39.3 31.7 19.1 50.8
MUFAs,3 g 20.0 12.1 32.1 12.3 7.4 19.7
PUFAs,3 g 2.9 1.8 4.7 2.8 1.8 4.6
TFAs,3 g 3.9 2.6 6.5 2.2 1.4 3.6
Protein,2 g 36.1 20.9 57.0 39.7 19.6 59.3
CHO,2 g 105.9 64.6 170.5 101.4 63.3 164.7
Free sugars, g 16.5 22.3 38.8 15.0 21.5 36.5
1Values are total energy and macronutrient quantities of each test meal according to modified and control diet. CHO, carbohydrate;
FA, fatty acid; TFA, trans fatty acid.
2Measurement of energy, total fat, protein, and carbohydrate content of the dairy product samples was conducted in duplicate by
SGS UK Ltd. (Ealing, London; ISO 17,025 accredited laboratory).
3Lipids extracted from the dairy product samples were analyzed in triplicate for FA composition by GC–flame ionization detection
using a standardized procedure, as described previously (16).
The energy, macronutrient, and FA compositions of the sequential
high-fat mixed meals consumed at breakfast and lunch are presented
in Table 1. Nutritional analysis (energy and macronutrient content)
of modified and control dairy samples was conducted in duplicate by
SGS United Kingdom Ltd. (Ealing, London; ISO 17,025 accredited
laboratory), as described elsewhere (16, 20). In brief, total fat content
was determined by low-resolution proton nuclear magnetic resonance.
Protein content was calculated by multiplying the total nitrogen, based
on the Dumas method, using a standard nitrogen conversion factor
of 6.25 to account for the fraction of nonprotein nitrogen in each
sample (21). Carbohydrate content was calculated by difference using
the Atwater general system (22). Using a standardized procedure (16),
lipids extracted from the modified and control dairy products were
analyzed in triplicate for FA composition by GC (Bruker 350; Bruker),
equipped with a flame ionization detector (FID) and 100-m fused silica
capillary column (CP-SIL 88; Agilent Technologies). The breakfast test
meal consisted of a toasted sandwich prepared with white bread (75 g;
Kingsmill; Allied Bakeries UK), Cheddar cheese (32.6 g) and butter
(modified: 32.6 g; control: 29.4 g), cornflakes (38 g, Kellogg’s UK)
served with ultra-high temperature (UHT) milk (195 g), and a milkshake
prepared with UHT milk (330 g) and strawberry sauce (19 g; Askeys;
Silver Spoon Company UK). The lunch test meal consisted of a toasted
sandwich prepared with white bread (60 g) with cheddar cheese (15 g)
and butter (modified: 19.8 g; control: 18.6 g) and a milkshake prepared
with UHT milk (modified: 352 g; control: 350 g) and strawberry sauce
(27 g).
Study visits
Participants completed a 4-d weighed food diary to assess habitual
dietary intake in the 1-wk run-in period to each study visit, which
was analyzed using Dietplan 7 Professional (Forestfield Software Ltd.)
(19). Habitual physical activity was assessed using the last 7-d version
of the International Physical Activity Questionnaire (IPAQ) long form.
For 24 h before each study visit, participants were instructed to avoid
alcohol and aerobic exercise and were provided with a low-fat evening
ready meal (<1.46 MJ; <7 g total fat) to standardize short-term fat
intake. Fasted (12 h) participants arrived at the Clinical Unit after only
drinking low-nitrate water overnight (Buxton Mineral Water; Nestlé
Waters UK).
Postprandial study visits (480 min) took place in a temperature-
controlled clinical room maintained between 22◦ ± 1◦C. Following
body-composition assessment, a cannula was inserted into an antecu-
bital vein of the forearm to allow for frequent blood sampling. After a
baseline blood sample and a 30-min period of supine rest, endothelial
function was assessed by FMD. Subsequently, a second baseline sample
was drawn (0 min) before a standardized breakfast test meal was
provided and consumed within a period of 20 min. Blood samples
were collected at regular intervals (every 30 min until 180 min, and
then every 60 min until 300 min). A standardized lunch test meal was
provided immediately after the 330-min blood draw and was consumed
within 15 min. Blood samples were then collected every 30 min up to
420 min, with the final sample obtained at 480 min after the breakfast
meal. FMD was assessed immediately after obtaining blood samples
at 180, 300, and 420 min postprandially. Participants remained in the
Clinical Unit for the duration of the study visit and were continuously
monitored. Low-nitrate water was permitted ad libitum during the study
visits.
Assessment of endothelial function
Three-lead electrocardiogram-gated brachial artery FMD measure-
ments were conducted in a standardized manner using a CX50
CompactXtreme Ultrasound System (Philips HealthCare, UK), as
previously reported (17, 23). For each participant, the initial baseline
scan image (visit 1) was used as a visual aid to help position the probe
on a similar section of the artery for subsequent FMD measurements.
Image sequences were assessed in a blinded manner using automated
wall-tracking software (Vascular Research Tools 5; Medical Imaging
Applications LLC). The %FMD response was calculated at each time
point as the relative increase in brachial artery diameter from baseline
to maximum dilation, expressed as a percentage.
Biochemical analyses
Plasma/serum separation was carried out, as previously detailed (17),
and samples were subsequently stored at −80◦C until analysis. For
determination of serum TG, nonesterified fatty acids (NEFAs), insulin,
and glucose, blood was drawn at all time points. Samples for serum
apoB were collected at 0, 60, 120, 180, 240, 300, 360, 390, 420,
and 480 min. At 180, 300, and 420 min (i.e., the designated FMD
time points), blood samples were also collected for the assessment of
plasma nitrite, nitrate, markers of endothelial activation, total lipid FA
responses, as well as whole blood culture for determination of LPS-
stimulated cytokine production.
Serum TG, apoB, NEFA, and glucose concentrations were quantified
on an ILAB 600 autoanalyzer (Instrumentation Laboratory Ltd.) with
the use of colorimetric assay kits (TG and glucose reagents: Instru-
mentation Laboratory Ltd.; NEFA reagent: Alpha Laboratories Ltd.)
and the use of an immunoturbidimetric assay (apoB reagent: Randox
Laboratories Ltd.). Serum insulin concentrations were determined by
ELISA (Dako UK Ltd.). Plasma nitrite and nitrate concentrations
were measured by HPLC (ENO-30; EiCom Corporation) with online
reduction of nitrate to nitrite and subsequent post-column derivatiza-
tion with the Griess reagent (ENO-30 Analyzer; Eicom Corporation)
(17). Plasma soluble vascular cell adhesion molecule 1 (sVCAM-1),
soluble intercellular adhesion molecule 1 (sICAM-1), E-selectin, and
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P-selectin concentrations were quantified by the Human Adhesion
Molecule Magnetic Luminex Performance Assay 4-Plex kit (R&D
Systems Europe Ltd.) with the use of Luminex 200 (Invitrogen) and
xPONENT software 3.1 (Luminex). All samples for each participant
were analyzed within a single run or kit to reduce interbatch variations.
Mean inter-assay CVs were <5% for the ILAB automated assays and
<10% for all other analyses.
LPS-stimulated cytokine analyses
For the determination of whole blood culture LPS-stimulated cytokines,
blood samples collected into K2-EDTA tubes were not centrifuged and
stored at 4◦C until processing as previously described (24). Briefly,
whole-blood samples were diluted 1:9 with Roswell Park Memorial
Institute 1640 medium (Sigma) supplemented with 1% antibiotics, 1%
l-glutamine, and 1% nonessential amino acids (Bioscience). Diluted
blood samples were cultured in 12-well plates (Greiner Bio-one) with
0.5 μg bacterial LPS/mL (Escherichia coli 026:B6; Sigma), at a final
concentration of 0.05 μg/mL. Whole blood cultures were subsequently
incubated at 37◦C for 24 h before centrifugation at 700 × g (1000 rpm)
for 5 min at room temperature to isolate the supernatant, which was
stored at −20◦C until analysis. Measurement of the monocyte count
of each sample was performed by the Pathology Department at the
Royal Berkshire Hospital (Reading, UK). A human cytokine premixed
5-Plex Panel (TNF-α, IL-6, IL-8, IL-1β, IL-10; R&D Systems Europe
Ltd.) and a Luminex 200 with xPONENT software 3.1 was used to
measure the concentrations of cytokines in the whole blood culture
supernatant in a 1:2 dilution. Cytokine production was corrected for
the number of monocytes in the whole-blood sample (micrograms × 103
monocytes).
Total lipid FA analyses
To assess changes in plasma FA status in response to our sequential 2-
meal fat challenge, we measured the plasma total lipid FA pool; this
pool is representative of immediate FA intake and gives an indication
of all FA-containing plasma lipid fractions, including cholesteryl esters,
NEFAs, phospholipids, and TG (25). Total lipid in 0.5 mL K3-EDTA
plasma was extracted using 5.0 mL chloroform-methanol [2:1, vol:vol;
Burdge et al. (24)]. After shaking for 15 min, the aqueous and solvent
layers were separated using centrifugation (1125 × g for 10 min at
4◦C), and the solvent layer dried under nitrogen at 40◦C. Dried lipid
was redissolved in 0.5 mL toluene and methylated by the addition of
1.0 mL 2% H2SO4 in methanol, and incubated for 2 h at 50◦C. After
neutralization, FAMEs were dissolved in hexane and centrifuged (1125
× g for 10 min at 4◦C). Resulting FAMEs were separated on a 100-m
fused silica capillary column (CP-SIL 88; Agilent Technologies) using
GC (Bruker 350; Bruker) with FID (26). Plasma FAMEs were identified
based on retention time comparisons with an authentic standard
(GLC #463; Nu-Chek-Prep, Inc.) and cross-referenced with previously
published chromatograms (27). Carbon deficiency in the FID response
for FAMEs containing 4- to 10-carbon atoms was accounted for using
a combined correction factor, which also converted FAMEs to FAs
(28).
Power calculation and statistical analyses
An a priori power calculation was performed for the nested study’s
primary outcome: change in the postprandial %FMD response. At
80% power and 5% significance, the minimum number of participants
required to complete both arms of the study in order to detect a
1.4% difference in the postprandial %FMD response between dairy
fat treatments with an SD of 2.3% was calculated as n = 45 (29).
To allow for a 15% drop-out rate, 52 participants were recruited into
the study and randomly assigned. A P value <0.05 was considered
significant for the primary outcome measure (postprandial %FMD
response; n = 45). No formal sample-size calculations were performed
for secondary outcomes variables, which included lipid metabolism
[TG, apoB, NEFA (n = 43–49)], glucose and insulin responses (n = 46),
circulating biomarkers of endothelial activation and inflammation
[nitrite and nitrate (n = 49); sVCAM-1, sICAM-1, E-selectin, and
P-selectin (n = 50); whole blood culture LPS-stimulated cytokines
(TNF-α, IL-6, IL-1β, IL-8, IL-10) ( n = 43–48)], and plasma total
lipid FA responses (n = 47–48). The FAs deemed relevant to our
dietary intervention (from 65 identified FAs) were selected for statistical
analysis a priori (19). P ≤ 0.01 was chosen a priori when assessing
significance for secondary outcome variables to acknowledge the issue
of multiplicity (17). Data presented in the text, tables, and figures
represent the unadjusted means ± SEMs, unless otherwise stated. We
chose to follow a per-protocol analysis approach a priori, as this was
a proof-of-concept study rather than a confirmatory trial (17). This
approach was taken, rather than intention-to-treat, as the trial was
designed to test efficacy (biological effects) rather than effectiveness
(30).
Summary measures of postprandial responses included the follow-
ing: AUC (calculated using the trapezoidal rule) and iAUC (calculated
by subtracting the fasting value from the AUC). Inclusion of the
iAUC summary measure provided an indication of the change in
the postprandial response to the sequential meal ingestion (31). The
time interval for AUC and iAUC was 420 min for %FMD, plasma
nitrite, nitrate, cell adhesion molecules, whole blood culture LPS-
stimulated cytokines, and total lipid FA responses and 480 min for
serum TG, apoB, glucose, and insulin responses. Due to the shape
of the postprandial NEFA time-course profile, AUC and iAUC for
this outcome were calculated from 120 min (approximate time of
NEFA minimum concentration) to 480 min postprandially (i.e., 360-
min interval) (32).
For postprandial variables with 13 (TG, NEFA, glucose, and insulin)
or 10 (apoB) time points, maximum (peak) concentration reached after
the test meal (Cmax) and time to reach maximum concentration (Tmax)
were also calculated. Additional outcome measures for NEFAs included
minimum concentration reached after the first test meal (Cmin), time
to reach minimum concentration (Tmin), and percentage of NEFA
suppression from fasting (32). A participant’s study visit data were
excluded from biochemical analyses if ≥40% of data or 3 consecutive
blood time points were missing. Since ingestion of sequential meals
leads to biphasic lipid and glycemic control responses (33, 34),
AUC and iAUC were also calculated for the time period between
breakfast and lunch (0–330 min) and post-lunch (330–480 min)
for serum TG, apoB, glucose, and insulin responses (i.e., variables
with ≥10 time points). As NEFA AUC and iAUC responses were
calculated from 120 to 480 min post-breakfast, it was not considered
physiologically relevant to calculate before and after the lunch for this
outcome.
Before analysis, suitable checks for normality were conducted
on all variables and the ln transformation was used for skewed
outcomes. Statistical analyses were performed with the use of SAS
9.4 University edition statistical software (SAS Institute, Inc.). The
baseline characteristics prior to the modified and control study visits
were assessed by paired t tests and chi-square test for continuous
and categorical variables, respectively. For all primary and secondary
outcomes, linear mixed-model analyses (PROC MIXED) were used to
evaluate fasting and treatment effects of meal dairy FA composition
on postprandial summary data. Postprandial time-course responses to
the meal dairy FA composition were also assessed using linear mixed
models. Treatment × time interaction effects were initially included in
the model and retained where found to be significant. In the absence of a
significant interaction, the interaction term was removed from the model
so that the overall treatment effect could be assessed. Fixed (period,
time, treatment, gender, age, and BMI) and random (participant) effects




A total of 52 participants successfully completed the study
(see Figure 1 for flowchart). There were no large biases in the
sex and age of individuals who were randomly assigned to the
intervention (n = 76) and those who completed the intervention
(n = 52; data not shown). Baseline characteristics of participants
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FIGURE 1 Flow of participants through the study. %FMD, percentage of flow-mediated dilatation response.
at the beginning of each acute study visit are presented in Table
2. The mean CVD risk score of participants at screening, as
assessed with the use of a modified Framingham risk score, was
3.0 ± 0.2. As outlined in Table 2, there were no differences
in the baseline characteristics or the habitual dietary intake of
participants prior to the modified and control study visits (P
> 0.01). Similarly, physical activity scores (as assessed by IPAQ)
did not significantly differ prior to the study visits (data not
shown). The sequential test meals were fully consumed and well
tolerated by all participants, without side effects.
Postprandial endothelial function response
The fasting %FMD response was comparable between study
days. There was no difference in the postprandial %FMD iAUC
or time-course profile (overall treatment) response following
consumption of the FA-modified and control sequential test
meals (Table 3; Supplemental Figure 2). However, there was a
tendency for an effect of meal dairy FA composition on the AUC
for the %FMD response, with a 4% higher response observed
after consumption of the FA-modified relative to the control
meals (P = 0.075).
Postprandial lipid, glucose, and insulin responses
Fasting serum concentrations of TGs, apoB, NEFAs, glucose,
and insulin were comparable between study days. There was
no differential impact of meal dairy FA composition on the
postprandial lipid (TGs and NEFAs), apoB, glucose, and insulin
summary measures (Table 4) or time-course responses (0–
480 min) (data not shown).
As outlined in Supplemental Table 1, subanalyses of AUC
and iAUC responses for the time period between the breakfast
and lunch meals (0–330 min) and after the lunch meal (330–
480 min) revealed differences in the TG and glucose responses
between the modified and control dairy fat meals. For the TG
response, there was a 2.8% higher iAUC after the modified
dairy compared with the control breakfast meal (0–330 min)
(P = 0.009). No other pre- or post-lunch differences in AUC
or iAUC were evident between the modified and control dairy
meals (i.e., P > 0.01).
Postprandial response for circulating markers of
endothelial activation and inflammation
Baseline (fasting) concentrations of all plasma markers of
endothelial activation and inflammation were comparable
between study days. Meal dairy FA composition had no effect
on postprandial endothelial activation or whole blood culture
LPS-stimulated cytokine summary measures (Table 3) or time-
course profile responses (data not shown), with the exception of
a tendency towards a 76% lower iAUC for the LPS-stimulated
whole-blood IL-1β response after consumption of the modified,
relative to the control, dairy fat meals (P = 0.024).
Postprandial plasma total lipid FA responses
As outlined in Table 5, baseline (fasting) abundance of all
plasma total lipid FAs was comparable between treatments.
The abundance of total SFAs, 14:0 (myristic acid), 15:0
(pentadecanoic acid), and 16:0 (palmitic acid) was significantly
lower following the FA-modified dairy compared with the
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TABLE 2 Baseline characteristics of participants at the









Chinese/Far Eastern 2 (4)
Asian 2 (4)
Body weight, kg 77.6 ± 1.9 77.8 ± 1.9
BMI, kg/m2 25.9 ± 0.5 25.9 ± 0.5
Waist circumference, cm 90.1 ± 1.5 89.2 ± 1.4
Blood pressure, mm Hg
Systolic 120 ± 2 120 ± 2
Diastolic 69 ± 1 70 ± 1
Fasting serum lipid profile, mmol/L
TC 5.55 ± 0.14 5.48 ± 0.12
LDL-C 3.46 ± 0.11 3.44 ± 0.10
HDL-C 1.52 ± 0.05 1.52 ± 0.04
Habitual dietary intake2
Energy, MJ/d 8.3 ± 0.3 8.5 ± 0.4
Total fat, %TE 35.9 ± 0.8 36.5 ± 0.9
SFAs, %TE 14.1 ± 0.5 13.9 ± 0.5
MUFAs, %TE 11.8 ± 0.4 11.9 ± 0.4
n–6 PUFAs, %TE 4.0 ± 0.2 4.6 ± 0.2
n–3 PUFAs, %TE 0.7 ± 0.0 0.8 ± 0.1
Total PUFAs, %TE 4.6 ± 0.2 5.3 ± 0.3
TFAs, %TE 0.9 ± 0.1 1.0 ± 0.1
Protein, %TE 17.0 ± 0.5 16.3 ± 0.5
Carbohydrates, %TE 46.7 ± 1.1 46.4 ± 1.0
Alcohol, %TE 2.9 ± 0.5 3.0 ± 0.5
Dietary fiber (AOAC), g/d 20.5 ± 1.0 20.2 ± 1.2
Sodium, g/d 2.6 ± 0.2 2.7 ± 0.2
1Values are given as untransformed and unadjusted means ± SEMs or n (%); n = 52
(overall group). Ethnicity was determined by self-report. No significant differences
were observed between the baseline characteristics of participants prior to modified
and control study visits, as assessed by paired t-tests (continuous variables) and
chi-square test (categorical variable). AOAC, Association of Analytical Chemists;
HDL-C, HDL cholesterol; LDL-C, LDL cholesterol; TC, total cholesterol; TFA, trans
fatty acid; %TE, percentage of total energy intake.
2Assessed by 4-d weighed food diet diaries in the 1-wk run-in period to each study
visit.
control dairy fat meals (all P < 0.0001 for the AUC, iAUC,
and the time-course interaction effect) (Table 5; Figure 2).
The abundance of 18:0 (stearic acid) over the postprandial
period was higher following the FA-modified compared with
the control dairy meals (P = 0.0002 and P = 0.001 for the AUC
response and the time-course interaction effect, respectively).
The abundance of total cis-MUFAs (predominantly cis-
9 18:1 (oleic acid)), total trans-18:1 (including trans-9 18:1
(elaidic acid) and trans-10 18:1 (octadecenoic acid)), and total
trans-MUFAs increased in the plasma total lipid FA pool
following the consumption of the FA-modified dairy fat meals
compared with control (P < 0.0001 for the AUC, iAUC, and
the time-course interaction effect) (Table 5; Figure 3). The
increase in the proportion of trans-11 18:1 (vaccenic acid) was
similar between control and FA-modified dairy meals (AUC,
iAUC, and time-course overall treatment effect: P > 0.05).
The abundance of conjugated linoleic acids also increased
following consumption of the modified, relative to the control,
dairy products (iAUC: P = 0.001; and the time-course overall
treatment effect: P = 0.006).
Discussion
This study highlights that, in adults at moderate CVD risk, acute
consumption of high-fat mixed meals rich in modified (SFA-
reduced, MUFA-rich) dairy products did not differentially affect
postprandial endothelial function or systemic biomarkers of
cardiometabolic health, relative to meals that contained control
(conventional) dairy products. Postprandial abundance of total
lipid FAs in the plasma following sequential FA-modified meal
consumption largely reflected the partial replacement of SFAs
with MUFAs in our dairy-rich test meals.
Endothelial dysfunction in the postprandial state has been
attributed to a progressive detrimental effect on CVD risk (12,
13). Here we demonstrate that acute consumption of dairy
meals varying in FA composition did not lead to different
postprandial endothelial function responses, although there
was a tendency for a beneficial increase in the AUC (but not
iAUC) for the %FMD response following consumption of the
modified dairy meals. This observation largely agrees with
previous acute investigations, which found that consumption
of high-fat mixed meals containing specific dietary fats (SFAs,
MUFAs, and n–6 PUFAs) did not differentially influence
impairments observed in postprandial endothelial function, as
assessed by FMD (35–37). In contrast, the parallel LIPGENE
postprandial study by Perez-Martinez et al. (38) found that
patients with the metabolic syndrome assigned to an MUFA-
rich test breakfast (65% total fat: 12% SFAs, 43% MUFAs)
had a significantly higher postprandial FMD response compared
with those assigned to other test meal conditions, including a
fat-matched SFA-rich breakfast (38% SFAs, 21% MUFAs) (38).
This study also highlighted that the availability of postprandial
NO synthase was greater and plasma sICAM-1 responses
were lower following the ingestion of a high-MUFA, relative
to the SFA-rich, meal, which contained predominantly butter
(38). Rundblad and colleagues (39) demonstrated that a high-
fat meal containing butter, but not fermented dairy products
(such as cheese), increased postprandial sICAM-1 and sVCAM-
1 concentrations. As our modified and control test meals
contained a combination of dairy products varying in food
matrix and fermentation, this may partly explain why we
did not have differential postprandial endothelial activation in
response to our high-fat dairy products. However, it is difficult
to draw meaningful comparisons between our study and the
findings of Perez-Martinez et al. (38), as the postprandial test
meal in the latter study was administered at the end of a 12-wk
period of dietary FA manipulation. However, another plausible
explanation for contrasting endothelial function outcomes
could be that our FA-modified and control sequential test meals
only had relatively modest difference (∼12 g) in both the content
of total SFAs and cis-MUFAs, compared with the LIPGENE
postprandial study where test-meal FA modification was not
limited specifically to dairy products (38).
Elevated systemic inflammation in the postprandial period
is linked to increased risk for atherosclerosis and insulin
resistance, with a single high-fat meal known to increase
proinflammatory cytokine concentrations, particularly IL-6
(40). Our study findings suggested that the FA composition of
the dairy products affected postprandial systemic inflammatory
responses to a similar extent, apart from a tendency for
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TABLE 3 Fasting and postprandial summary endothelial function and circulating biomarkers of
endothelial activation and inflammatory responses following sequential high-fat mixed-meal




Fasting,2 % 4.50 ± 0.27 4.66 ± 0.28 0.112
AUC,2 % × min 2040 ± 108 1960 ± 111 0.075
iAUC, % × min 146 ± 78 5 ± 81 0.315
Plasma nitrite
Fasting, μmol/L 0.14 ± 0.02 0.16 ± 0.02 0.570
AUC, μmol/L × min 64.6 ± 7.9 65.5 ± 8.5 0.980
iAUC, μmol/L × min 4.3 ± 4.9 -0.8 ± 4.7 0.480
Plasma nitrate
Fasting,2 μmol/L 16.1 ± 0.9 16.6 ± 1.0 0.970
AUC,2 μmol/L × min 5280 ± 285 5290 ± 271 0.990
iAUC, μmol/L × min − 1480 ± 249 − 1700 ± 248 0.730
Adhesion molecules
Plasma sVCAM-1
Fasting,2 ng/mL 540 ± 32 554 ± 31 0.623
AUC,2 ng/mL × min 226 ± 12 237 ± 13 0.180
iAUC, ng/mL × min -0.8 ± 3.4 3.7 ± 4.5 0.489
Plasma sICAM-1
Fasting, ng/mL 88.2 ± 6.9 84.3 ± 7.3 0.534
AUC, ng/mL × min 37.8 ± 3.0 36.4 ± 3.1 0.461
iAUC, ng/mL × min 0.7 ± 1.2 1.0 ± 1.5 0.959
Plasma E-selectin
Fasting, ng/mL 25.2 ± 2.0 25.2 ± 1.7 0.953
AUC, ng/mL × min 10.3 ± 0.8 10.3 ± 0.7 0.992
iAUC, ng/mL × min − 0.28 ± 0.2 − 0.27 ± 0.1 0.934
Plasma P-selectin
Fasting,2 ng/mL 25.7 ± 1.4 26.7 ± 1.5 0.257
AUC,2 ng/mL × min 10.7 ± 0.6 10.7 ± 0.6 0.912
iAUC, ng/mL × min − 0.05 ± 0.2 − 0.51 ± 0.2 0.090
Whole blood culture LPS-stimulated cytokines (per 103
monocytes)
TNF-α
Fasting,2 μg 12.3 ± 0.9 11.5 ± 0.6 0.729
AUC,2 mg × min 5.00 ± 0.3 4.99 ± 0.3 0.250
iAUC, mg × min − 0.18 ± 0.2 0.16 ± 0.2 0.319
IL-6
Fasting,2 μg 82.6 ± 4.3 79.1 ± 4.2 0.869
AUC,2 mg × min 32.8 ± 1.7 33.2 ± 1.7 0.453
iAUC, mg × min − 1.88 ± 1.0 0.03 ± 1.2 0.343
IL-1β
Fasting,2 μg 27.4 ± 1.5 26.2 ± 1.3 0.516
AUC,2 mg × min 11.9 ± 0.6 12.5 ± 0.6 0.181
iAUC, mg × min 0.36 ± 0.4 1.50 ± 0.4 0.024
IL-8
Fasting, μg 124 ± 10 130 ± 10 0.653
AUC, mg × min 48.6 ± 4.1 51.3 ± 6.0 0.502
iAUC, mg × min − 3.35 ± 2.4 − 3.13 ± 4.4 0.921
IL-10
Fasting, μg 0.77 ± 0.08 0.91 ± 0.09 0.060
AUC,2 mg × min 0.28 ± 0.02 0.35 ± 0.04 0.083
iAUC, mg × min − 0.04 ± 0.02 − 0.03 ± 0.02 0.645
1Values are untransformed and unadjusted means ± SEMs. For all variables, n = 50, except for nitrite and nitrate, n = 49; TNF-α,
IL-1β, IL-6, IL-10, n = 48; %FMD response, n = 45; and IL-8, n = 43. The time interval for AUC and iAUC: 420 min for all variables.
Linear mixed-model analyses were used to calculate overall treatment effect in postprandial summary measures, with adjustments
made for fixed effects of period, treatment, gender, age, and BMI. Participant was included as a random effPostprandial endothelial
function response intercellular adhesion molecule 1; sVCAM-1, soluble vascular adhesion molecule 1, %FMD, percentage of
flow-mediated dilatation.
2Indicates data were log-transformed prior to analysis.
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TABLE 4 Fasting and postprandial serum lipids, glucose, and insulin responses following
sequential high-fat mixed-meal challenges rich in fatty acid–modified or conventional (control) dairy
products in adults with moderate cardiovascular disease risk1
Modified Control P
TGs2
Fasting, mmol/L 1.25 ± 0.08 1.15 ± 0.06 0.163
Cmax, mmol/L 2.83 ± 0.15 2.58 ± 0.12 0.080
Tmax, min 355 ± 9 334 ± 9 0.045
AUC, mmol/L × min 950 ± 53 879 ± 41 0.163
iAUC, mmol/L × min 351 ± 26 325 ± 23 0.651
apoB
Fasting,2 mg/mL 1.01 ± 0.03 1.00 ± 0.03 0.324
Cmax,2 mg/mL 1.03 ± 0.03 1.04 ± 0.03 0.725
Tmax, min 212 ± 24 207 ± 22 0.790
AUC,2 mg/mL × min 472 ± 14 470 ± 14 0.477
iAUC, mg/mL × min -14 ± 3 -11 ± 2 0.284
NEFAs
Fasting,2 μmol/L 557 ± 25 554 ± 31 0.412
Cmin30–330,2 μmol/L 113 ± 5 111 ± 6 0.212
Tmin30–330,2 min 142 ± 6 135 ± 7 0.394
Suppression30–330,2 % 79 ± 1 77 ± 2 0.318
Cmax120–480,2 μmol/L 436 ± 19 481 ± 21 0.083
Tmax120–480,2 min 361 ± 5 360 ± 6 0.806
AUC120–480,2 mmol/L × min 91 ± 3 97 ± 4 0.192
iAUC120–480, mmol/L × min 45 ± 3 51 ± 4 0.223
Glucose
Fasting,2 mmol/L 5.41 ± 0.11 5.39 ± 0.10 0.870
Cmax,2 mmol/L 8.27 ± 0.22 7.99 ± 0.21 0.086
Tmax, min 230 ± 25 243 ± 25 0.620
AUC,2 mmol/L × min 2940 ± 64 2870 ± 64 0.055
iAUC,2 mmol/L × min 347 ± 41 286 ± 40 0.145
Insulin
Fasting, pmol/L 41.2 ± 3.6 41.3 ± 4.0 0.948
Cmax, pmol/L 551 ± 51 509 ± 42 0.108
Tmax, min 170 ± 25 222 ± 25 0.062
AUC, μmol/L × min 121 ± 11 114 ± 9 0.204
iAUC, μmol/L × min 102 ± 9 95 ± 8 0.151
1Values are untransformed and unadjusted means ± SEMs. For all variables, n = 46, except n = 49 for apoB and n = 43 for NEFAs.
Time interval for AUC and iAUC: 480 min for all variables, except for 360 min NEFA. Linear mixed-model analyses were used to
calculate overall treatment effect in postprandial summary measures, with adjustments made for fixed effects of period, treatment,
gender, age, and BMI. Participant was included as a random effect. For all outcome measures, P ≤ 0.01 was deemed significant to
acknowledge multiplicity. Cmax, maximum concentration; Cmin, minimum concentration; iAUC, incremental AUC; NEFA,
nonesterified fatty acid; TG; triacylglycerol; Tmax, time to reach maximum concentration; Tmin, time to reach minimum
concentration.
2Indicates data were log-transformed prior to analysis.
a potentially favorable reduction in the whole blood cul-
ture LPS-stimulated IL-1β iAUC response following modified
dairy meals. This finding may be related to higher MUFA
content of these dairy products since a study conducted
in insulin-resistant patients found the fasting plasma FA
concentration of oleic acid (cis-9 18:1) to be negatively
associated with systemic IL-1β concentrations (41). Although
not directly comparable, our study agrees with a previous
observation highlighting that the dairy content of high-fat
meals did not differently affect postprandial IL-6 and TNF-
α responses in healthy men (42). Similarly, the FA quality
of high-fat meals did not elicit differences in postprandial
IL-6 concentrations in metabolic syndrome patients (43) or
obese and lean women (44).
We observed no differential effect of our sequential dairy
test meal challenge on postprandial lipid, glucose, or insulin
concentrations. This finding is largely in agreement with
previous acute studies that compared the metabolic effects of
sequential high-fat meals rich in SFAs, MUFAs, and n–6 PUFAs
among postmenopausal women (35) and single high-fat meals
(40 g total fat) containing different proportions of MUFAs
(12%, 17%, and 24% of energy) in healthy men (45). In
subanalyses, we found a higher TG iAUC response following
the modified breakfast meal (0–330 min), relative to the control
meal. In line with this, Tholstrup et al. (46) observed higher
postprandial plasma and chylomicron TG responses to a high-
fat meal containing FA-modified butter at 4 h postprandially in
healthy young men, when compared with a conventional Danish
butter. However, postprandial responses were assessed after a
4-wk isoenergetic dietary intervention (with 16% of 12:0–16:0
replaced mainly with cis-9 18:1 and 18:0 in the FA-modified
butter diet) (46).
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TABLE 5 Fasting and postprandial summary responses of selected plasma total lipid fatty acids
following sequential high-fat mixed-meal challenges rich in fatty acid–modified or conventional




Fasting, g/100 g total FAs 0.09 ± 0.01 0.09 ± 0.01 0.489
AUC,2 g/100 g total FAs × min 47 ± 7 68 ± 13 0.446
iAUC,2 g/100 g total FAs × min 7 ± 7 29 ± 14 0.446
14:02
Fasting, g/100 g total FAs 0.98 ± 0.05 0.98 ± 0.05 0.861
AUC, g/100 g total FAs × min 689 ± 24 835 ± 28 <0.0001
iAUC, g/100 g total FAs × min 279 ± 15 424 ± 25 <0.0001
15:0
Fasting, g/100 g total FAs 0.23 ± 0.01 0.24 ± 0.01 0.468
AUC, g/100 g total FAs × min 119 ± 2 138 ± 3 <0.0001
iAUC,2 g/100 g total FAs × min 22 ± 1 39 ± 2 <0.0001
16:0
Fasting,2 g/100 g total FAs 22.89 ± 0.25 22.67 ± 0.19 0.451
AUC,2 g/100 g total FAs × min 9760 ± 91 10,400 ± 73 <0.0001
iAUC, g/100 g total FAs × min 142 ± 33 837 ± 48 <0.0001
17:0
Fasting, g/100g total FAs 0.28 ± 0.01 0.28 ± 0.01 0.537
AUC,2 g/100 g total FAs x min 117 ± 3 128 ± 3 0.603
iAUC,2 g/100 g total FAs × min 1 ± 3 12 ± 4 0.458
18:0
Fasting,2 g/100 g total FAs 7.50 ± 0.13 7.33 ± 0.12 0.103
AUC,2 g/100 g total FAs × min 3410 ± 42 3260 ± 45 0.0002
iAUC, g/100 g total FAs × min 255 ± 38 181 ± 43 0.132
Total SFAs3
Fasting,2 g/100 g total FAs 33.30 ± 0.36 32.91 ± 0.28 0.277
AUC,2 g/100 g total FAs × min 14,700 ± 126 15,400 ± 111 <0.0001
iAUC, g/100g total FAs × min 741 ± 69 1580 ± 109 <0.0001
MUFAs
cis-9 18:1
Fasting,2 g/100 g total FAs 21.75 ± 0.38 21.56 ± 0.35 0.923
AUC,2 g/100 g total FAs × min 9350 ± 161 8730 ± 146 <0.0001
iAUC, g/100 g total FAs × min 219 ± 76 -323 ± 67 <0.0001
Total cis-18:14
Fasting,2 g/100 g total FAs 23.53 ± 0.32 23.36 ± 0.30 0.975
AUC,2 g/100 g total FAs × min 10,100 ± 133 9460 ± 124 <0.0001
iAUC, g/100 g total FAs × min 204 ± 63 − 353 ± 56 <0.0001
Total cis-MUFAs5
Fasting,2 g/100 g total FAs 25.19 ± 0.36 24.99 ± 0.32 0.996
AUC,2 g/100 g total FAs × min 10,800 ± 150 10,300 ± 139 <0.0001
iAUC,2 g/100 g total FAs × min 272 ± 67 − 238 ± 59 <0.0001
trans-9 18:1
Fasting, g/100 g total FAs 0.12 ± 0.01 0.12 ± 0.01 0.309
AUC, g/100 g total FAs × min 85 ± 3 53 ± 2 <0.0001
iAUC,2 g/100 g total FAs × min 33 ± 5 4 ± 4 <0.0001
trans-10 18:1
Fasting,2 g/100 g total FAs 0.09 ± 0.01 0.10 ± 0.01 0.239
AUC, g/100 g total FAs × min 222 ± 9 57 ± 2 <0.0001
iAUC, g/100 g total FAs × min 184 ± 9 16 ± 3 <0.0001
trans-11 18:1
Fasting,2 g/100 g total FAs 0.14 ± 0.01 0.15 ± 0.01 0.421
AUC,2 g/100 g total FAs × min 100 ± 3 102 ± 2 0.198
iAUC, g/100 g total FAs × min 41 ± 3 41 ± 3 0.811
Total trans-18:16
Fasting,2 g/100 g total FAs 0.56 ± 0.03 0.57 ± 0.03 0.679
AUC,2 g/100 g total FAs × min 657 ± 19 358 ± 7 <0.0001
iAUC, g/100 g total FAs × min 422 ± 22 118 ± 12 <0.0001
(Continued)












Fasting,2 g/100 g total FAs 1.03 ± 0.03 1.02 ± 0.03 0.934
AUC,2 g/100 g total FAs × min 855 ± 21 552 ± 9 <0.0001
iAUC, g/100 g total FAs × min 424 ± 22 122 ± 13 <0.0001
Total TFAs8
Fasting, g/100 g total FAs 1.36 ± 0.04 1.36 ± 0.04 0.699
AUC, g/100 g total FAs × min 1000 ± 24 695 ± 11 <0.0001
iAUC, g/100 g total FAs × min 434 ± 25 124 ± 16 <0.0001
PUFAs
Total CLAs9
Fasting,2 g/100 g total FAs 0.19 ± 0.01 0.20 ± 0.01 0.561
AUC,2 g/100 g total FAs × min 118 ± 4 108 ± 4 0.019
iAUC,2 g/100g total FAs × min 39 ± 3 25 ± 2 0.001
Total n–3 PUFAs10
Fasting,2 g/100 g total FAs 3.72 ± 0.12 3.86 ± 0.15 0.426
AUC,2 g/100 g total FAs × min 1460 ± 50 1480 ± 52 0.786
iAUC,2 g/100 g total FAs × min − 106 ± 24 − 143 ± 29 0.211
Total n–6 PUFAs11
Fasting, g/100 g total FAs 34.94 ± 0.66 35.43 ± 0.59 0.544
AUC,2 g/100 g total FAs × min 13,400 ± 241 13,600 ± 217 0.440
iAUC,2 g/100 g total FAs × min -1250 ± 138 -1250 ± 139 0.896
1Values are untransformed and unadjusted means ± SEMs. For all variables, n = 47–48. The time interval for AUC and iAUC:
420 min for all variables. Linear mixed-model analyses were used to calculate overall treatment effect in postprandial summary
measures, with adjustments made for fixed effects of period, treatment, gender, age, and BMI. Participant was included as a
random effect. For all outcome measures, P ≤ 0.01 was deemed significant to acknowledge multiplicity. CLA, conjugated linoleic
acid; FA, fatty acid; iAUC, incremental AUC; TFA, trans fatty acid.
2Indicates data were log-transformed prior to analysis.
3Total SFAs include: 6:0, 7:0, 8:0, 9:0, 10:0, 11:0, 12:0, 13:0 iso, 13:0 anteiso, 13:0, 14:0 iso, 14:0, 15:0 anteiso, 15:0, 16:0 iso, 16:0,
17:0 iso, 17:0 anteiso, 17:0, 18:0 iso, 18:0, 19:0, 20:0, 22:0, and 24:0.
4Total cis-18:1 include: cis-9 18:1, cis-11 18:1, cis-12 18:1, cis-13 18:1, cis-14 18:1, cis-15 18:1, and cis-16 18:1.
5Total cis-MUFAs include: cis-9 10:1, cis-10 11:1, cis-9 12:1, 13:1 (unknown bond position), cis-9 14:1, cis-10 15:1, cis-9 16:1, cis-13
16:1, cis-10 17:1, cis-9 17:1, cis-9 18:1, cis-11 18:1, cis-12 18:1, cis-13 18:1, cis-14 18:1 cis-15 18:1, cis-16 18:1, 19:1 (unknown bond
position), cis-5 20:1, cis-8 20:1, cis-11 20:1, cis-13 22:1, and cis-15 24:1.
6Total trans 18:1 include: trans-4 18:1, trans-6 18:1, trans-7 18:1, trans-8 18:1, trans-9 18:1, trans-10 18:1, trans-11 18:1, trans-12
18:1, trans-15 18:1, and trans-16 18:1.
7Total trans-MUFAs include: trans-9 14:1, trans-9 16:1, trans-11 16:1, trans-13 16:1, trans-10 17:1, trans-4 18:1, trans-6 18:1, trans-7
18:1, trans-8 18:1, trans-9 18:1, trans-10 18:1, trans-11 18:1, trans-12 18:1, trans-15 18:1, and trans-16 18:1.
8Total TFAs include: trans-18:1, trans-11, 15 18:2, trans-9, 12 18:2, cis-9, trans-13 18:2, cis-10, trans-14 18:2, cis-9, trans-12 18:2,
trans-9, 12 18:2, trans-11, cis-15 18:2, and trans-12, cis-15 18:2.
9Total CLAs include a peak, which contains mainly cis-9, trans-11 CLA, but also trans-7, cis-9 CLA, trans-8, cis-10 CLA, and trans-6,
cis-8 CLA.
10Total n–3 PUFAs include: trans-11, 15 18:2, trans-11, cis-15 18:2, trans-12, cis-15 18:2, cis-9, 12, 15, 18:3, cis-11, 14, 17 20:3, cis-5,
8, 11, 14, 17 20:5, cis-7, 10, 13, 16, 19 22:5, and cis-4, 7, 10, 13, 16, 19 22:6.
11Total n–6 PUFAs include: trans-9, 12 18:2, cis-9, trans-12 18:2, trans-9, cis-12 18:2, cis-9, 12 18:2, cis-6, 9, 12 18:3, cis-11, 14 20:2,
cis-8, 11, 14 20:3, cis-5, 8, 11, 14 20:4, cis-13, 16 20:2, and cis-7, 10, 13, 16 22:4.
Supplementation of the dairy-cow diet with unprotected
HOS oil by our group led to a proportion of milk SFAs being
replaced by cis-MUFAs, as well as trans-MUFAs through the
process of biohydrogenation of unsaturated FAs by rumen
bacteria (16). Consequently, our FA-modified, 2-meal challenge
each contained a 3-g (2-fold) higher trans-MUFA content
compared with the conventional dairy meals. Our bovine
supplementation strategy also led to alterations in the trans-
18:1 isomer profile, with a shift from the formation of
predominantly trans-11 in conventional milk fat toward a
greater proportion of trans-10 (and to a lesser extent, trans-
9) intermediates in modified milk fat, which was primarily as
a result of isomerization of cis-9 18:1 within the rumen (16).
The postprandial composition of the plasma total lipid FA
pool largely resembled that of the ingested dairy fats (16). We
observed a reduction in total SFAs (including 14:0, 15:0, and
16:0) and an increase in the abundance of 18:0, total cis-MUFAs
(primarily cis-9 18:1), and total trans-MUFAs (particularly
trans-9 and trans-10 18:1 isomers) in the plasma total lipid
pool following consumption of the sequential modified dairy,
relative to the control, meals. It may be considered that the
higher total trans-18:1 content of our FA-modified dairy meals,
and abundance of trans-18:1 isomers in the plasma lipid pool,
might have counteracted the impairment of endothelial function
and inflammation in response to the sequential high-fat meals
linked to favorable postprandial changes in the abundance
of plasma total SFAs and cis-MUFAs following consumption
of the FA-modified dairy meals. Indeed, increased intake of
trans-9 18:1 (elaidic acid), one of the major trans isomers
produced industrially by the partial hydrogenation of vegetable
oils, is adversely linked to cardiovascular health outcomes (47,
48). Cross-sectional data generated from the Nurses’ Health
Study illustrated that intake of trans-9 18:1 was positively
associated with E-selectin, sVCAM-1, sICAM-1, and soluble
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FIGURE 2 Time-course profiles of postprandial plasma total lipid FAs in response to sequential high-fat mixed-meal challenges (breakfast at
0 min and lunch at 330 min) rich in FA-modified or conventional dairy products (control) in adults at moderate cardiovascular risk for total SFAs
(A), 14:0 (B), 15:0 (C), 16:0 (D), and 18:0 (E). Values are untransformed and unadjusted means ± SEMs, n = 47–48. The dotted lines represent the
timing of the second meal (330 min). Linear mixed-model analysis was used to explore the effects of treatment and time, with an adjustment
made in all cases for fixed effects of period, time, treatment, gender, age, and BMI. Participant was included as a random effect. P ≤ 0.01 was
deemed significant to acknowledge multiplicity. FA, fatty acid.
TNF-α receptor 2 in women (49). In support of differences in
biological mechanisms between trans-18:1 isomers, Iwata et al.
(50) reported that a 180-min treatment of human endothelial
cells with increasing concentrations (≤0.1 mM) of trans-9 18:1
was associated with increased NF-κB activation and impaired
NO production, whereas trans-vaccenic acid (trans-11 18:1)
was not related to either of these responses. Taking into
consideration that the concentrations of total plasma trans
FAs in humans have been shown to be as high as 0.6 mM
in the fasted state (51), the FA concentrations used in the
aforementioned in vitro study could be deemed physiological
(52).
Strengths of the current study include the double-blinded,
randomized design and use of a sequential high-fat mixed-
meal challenge, which provided a more accurate reflection of
Western dietary patterns (32). We studied adults at moderate
CVD risk but acknowledge that our findings may not be
generalizable across different groups, including young, healthy
populations. Our modified foods largely reflected the natural FA
profile of milk produced by an HOS-oil bovine feeding strategy
(16) but our strategy increased the concentration of trans-18:1
isomers in milk, which were incorporated into the plasma total
lipid pool following acute consumption. Further research is
warranted to examine the cardiometabolic health effects of FA-
reformulated dairy foods that are produced following rumen-
protected bovine supplementation strategies, and thus contain
a reduced formation of trans-18:1 intermediates.
In conclusion, consumption of sequential high-fat meals rich
in FA-modified dairy products led to a lower abundance of total
SFAs (including 14:0, 15:0, and 16:0) and higher abundance
of 18:0 and total cis- and trans-MUFAs (predominantly trans-
18:1 isomers) in the postprandial plasma total lipid pool, when
compared with control dairy meals. Meal dairy FA consumption
did not elicit significant differences in postprandial endothelial
function or systemic cardiometabolic risk markers in our cohort
of adults at moderate CVD risk. Previous work has shown
that chronic consumption of FA-modified dairy products may
have a beneficial impact on the fasting cholesterol profile (17,
53) and endothelial function (17). As the FA composition of
the background diet may be of greater health importance than
isolated acute differences in FA intake (54), the postprandial
effects of long-term FA-modified dairy product consumption
need further investigation.
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